(Bloomberg) -- GSK Plc’s Chief Executive Officer Emma Walmsley ... “We should wait and see what the facts are when they come through.” The CEO also commented on Trump’s tariff threats.

Total Q4 sales GBP 8.12B up 1% AER; up 4% CER. Vaccines sales down 12%. Specialty Medicines sales up 17%. HIV sales up 14%. Oncology up 72%.

GSK (GSK.L, GSK) reported fiscal 2024 profit before tax of 3.5 billion pounds, down 43% at AER, or down 34% at CER from prior year.

GSK has today posted a better-than-expected fourth quarter and lifted its 2031 sales target to nearly $50 billion as the ...

GSK said pretax profit in 2024 fell 43% to GBP3.48 billion from GBP6.06 billion a year prior, though revenue increased 3.5% to GBP31.38 billion from GBP30.33 billion, ahead of the GBP31.05 billion ...

GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its return to cancer medicines. While GSK already agreed to multiple deals in ...